PHARMACY

FDA approves Lupin’s generic Klor-Con

BY David Salazar
MUMBAI — The Food and Drug Administration has approved Lupin subsidiary Gavis Pharmaceuticals’ generic of Klor-Con  (potassium chloride) extended-release tablets, the company announced Wednesday. The drug is indicated to treat patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and patients with hypokalemic familial periodic paralysis. It’s also indicated to prevent hypokalemia in patients at risk if they developed it — for example, patients with significant cardiac arrhythmias. 
 
Lupin’s generic will be available in 600- and 800-mg dosage strengths. U.S. sales for the product were $101.3 million for the 12 months ended June 2016, according to IMS Health. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Endo names new president, U.S. branded pharmaceuticals

BY David Salazar
DUBLIN — Endo International this week announced the appointment of Joseph Ciaffoni as president, U.S. branded pharmaceuticals, effective Aug. 15. Ciaffoni was most recently SVP global specialty medicines group for Biogen, where he led development and execution of global strategy for the company’s marketed and pipeline products. 
 
"We are excited to announce the addition of Joe to the Endo executive team. His industry experience is extensive and includes building commercial businesses, leading multi-function organizations and achieving stellar results across primary care, specialty and rare disease markets,” Endo president and CEO Rajiv De Silva said. “His proven track record of success across nearly 20 product launches and the commercialization of more than 70 products will be instrumental as we continue to focus on strategically growing our U.S. Branded business.”
 
Ciaffoni began at Biogen in 2012, and held various titles there, including SVP U.S. commercial. He has also previously served as EVP and  CFO of Shionogi and president of Shionogi Pharmaceuticals, as well as VP sales for Schering-Plough (now Merck). 
 
“I am thrilled to be joining Endo at a time of such significant opportunity for the business,” Ciaffoni said. “I look forward to leading Endo's U.S. branded pharmaceutical business, driving the development and execution of Endo's branded strategy and accelerating key growth drivers while, ultimately, helping improve patients' lives.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Mediware releases CareTrend for specialty pharmacies

BY DSN STAFF
LENEXA, Kan. — Healthcare software company Mediware Information Systems announced Wednesday that its CareTrend platform is now available for specialty pharmacies. The new platform looks to simplify prescription procession, pharmacy workflow, reimbursement and reporting. 
 
CareTrend allows users to manage their entire workflow operations from a single dashboard that can track output and identify delays while tracking employee productivity in real time. The platform also includes expanded workflow queues that pharmacists can use to increase daily processing through quick-fill options and streamlined order management. CareTrend can also provide customized reporting to meet customer needs.
 
“We have incorporated customer feedback into our CareTend solution so that today’s specialty pharmacies can thrive using the only complete system designed for this market, “ VP and general manager of Mediware’s home care solutions division,  Paul O’Toole, said. “From intake to dispensing to working and reporting, our suite eliminates the need for multiple systems by having everything in one integrated solution.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?